Amgen Inc. (AMGN)
Can Amgen's MariTide Take on Leaders in the Obesity Space?
AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Can Amgen Sustain Its Rally In 2026
Amgen Inc. ends 2025 on a high note. Thanks to strong sales of Repatha and Imdelltra, it raised its full-year 2025 revenue guidance from $35-$36 billion to $35.8-$36.6 billion. So, sales of Repatha, a cholesterol-lowering medication, were $794 million in Q3, up 40% YoY.
Amgen Strikes Drug Pricing Deal With Trump: What Investors Should Know
AMGN signs a pricing deal with the Trump administration, cutting U.S. drug costs, expanding DTC access and securing tariff relief tied to domestic investment.
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?
NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 Healthcare Giants Just Raised Dividends—Here's Who Pays the Most
Major players in healthcare are increasing their commitments to return capital to shareholders, resulting in significantly higher dividends. Recent dividend announcements from major companies in the sector highlight evolving capital return strategies.
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
The latest trading day saw Amgen (AMGN) settling at $325.31, representing a +2.38% change from its previous close.
Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis
AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Why Is Amgen (AMGN) Up 8% Since Last Earnings Report?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?
